2024.07

The company joined Baheal Pharmaceutical Co., Ltd. (SZ. 301015) as a subsidiary.

2023.06

The company was merged into Shanghai Baheal Pharmaceutical Co., Ltd.

2021.08

Passed the assessment and certification of the Management System for the Integration of Informatization and Industrialization.

2018.11

Obtained project approval for the National Science and Technology Major Project on Major New Drug Development.

2018.04

Obtained project approval under the Key R&D Program of Shandong Province (Major Scientific and Technological Innovation Project).

2017.12

Designated by the National Health and Family Planning Commission as one of the pharmaceutical enterprises undertaking major national projects of the 13th Five-Year Plan. It is the only selected pharmaceutical enterprise in Qingdao and one of merely three such enterprises in Shandong Province.

2016.10

Achieved zero observations in the first U.S. FDA cGMP on-site inspection.

2015.01

Completed the renewal of the Drug Production License and passed the GMP certification inspection.

2014.06

The new Jimo manufacturing base was officially put into operation.

2005.12

Completed industrial and commercial registration for the name change to Qingdao Baheal Pharmaceutical Co., Ltd.